NDAINJECTIONINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORLOPAM (fenoldopam mesylate) is an intravenous dopamine D1-receptor agonist approved in 1997 for short-term management of severe hypertension. It works by selective activation of dopamine-1 receptors to produce vasodilation and reduce blood pressure in acute care settings. The drug is typically administered as an IV infusion in hospital and critical care environments.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating likely team consolidation and focus on differentiation or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CORLOPAM offers limited job openings (0 linked roles identified) and reflects a mature, niche product in its LOE phase. Career progression on this asset is constrained; professionals should expect defensive commercial strategies and potential role migration to other Pfizer acute-care franchises.
Brand ManagerRegional Sales Manager
Worked on CORLOPAM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.